Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AXCELLA HEALTH INC.

(AXLA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/16/2021 09/17/2021 09/20/2021 09/21/2021 09/22/2021 Date
3.24(c) 3.23(c) 3.09(c) 3.15(c) 3.07(c) Last
22 554 64 578 65 360 30 287 121 646 Volume
+1.25% -0.31% -4.33% +1.94% -2.54% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -67,4 M - -
Net cash position 2021 25,1 M - -
P/E ratio 2021 -1,72x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -82,7 M - -
Net Debt 2022 0,57 M - -
P/E ratio 2022 -1,44x
Yield 2022 -
Capitalization 117 M 117 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 59
Free-Float 76,7%
More Financials
Company
Axcella Health Inc. is a biotechnology company. The Company focuses on research and development of multifactorial interventions to support health and address dysregulated metabolism across a spectrum of consumers. It designs and develops endogenous metabolic modulators. Its AXA Development Platform produces a pipeline of AXA candidates with programs in liver, muscle and blood. The CompanyÔÇÖs wholly owned pipeline... 
More about the company
Ratings of Axcella Health Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about AXCELLA HEALTH INC.
04:11aJOHN CHEN : Stock Futures -3-
DJ
09/22AXCELLA HEALTH : Goldman Sachs Downgrades Axcella Health to Neutral Rating From Buy, Adjus..
MT
09/07AXCELLA HEALTH INC. : Entry into a Material Definitive Agreement, Creation of a Direct Fin..
AQ
09/07Axcella Health Inc. Enters into Loan and Security Agreement
CI
09/07AXCELLA : Announces Upcoming Investor Conference Presentation
BU
08/16AXCELLA : Announces Publication in The American Journal of Gastroenterology of Positive Re..
BU
08/16Axcella Announces Publication in The American Journal of Gastroenterology of Positive R..
CI
07/30AXCELLA HEALTH : JPMorgan Downgrades Axcella Health to Underweight From Neutral
MT
07/30AXCELLA HEALTH : 10q q2 2021 pdf
PU
07/29AXCELLA HEALTH : Management's Discussion and Analysis of Financial Condition and Results o..
AQ
07/29AXCELLA HEALTH INC. : Results of Operations and Financial Condition (form 8-K)
AQ
07/29AXCELLA : Reports Second Quarter Financial Results and Provides Business Update
BU
07/29AXCELLA HEALTH : Earnings Flash (AXLA) AXCELLA Posts Q2 Loss $-0.42, vs. Street Est of $-0..
MT
07/29Axcella Health Inc. Announces Earnings Results for the Second Quarter and Six Months En..
CI
07/29Axcella Health Inc. Appoints Virginia Dean as Senior Vice President and Chief People Of..
CI
More news
News in other languages on AXCELLA HEALTH INC.

- No features available -

More news
Analyst Recommendations on AXCELLA HEALTH INC.
More recommendations
Chart AXCELLA HEALTH INC.
Duration : Period :
Axcella Health Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AXCELLA HEALTH INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 3,07 $
Average target price 14,63 $
Spread / Average Target 376%
EPS Revisions
Managers and Directors
William R. Hinshaw President, Chief Executive Officer & Director
Laurent Chardonnet Chief Financial Officer & Senior Vice President
David R. Epstein Chairman
Tony Tramontin Chief Scientific Officer, Senior VP-R&D
Alison Schecter President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
AXCELLA HEALTH INC.-40.85%117
GILEAD SCIENCES, INC.22.52%89 497
BIONTECH SE316.17%81 938
WUXI APPTEC CO., LTD.36.63%69 841
REGENERON PHARMACEUTICALS33.94%67 273
VERTEX PHARMACEUTICALS-22.03%47 805